Sign in

You're signed outSign in or to get full access.

Stephen K. Roddenberry

Lead Independent Director at WORLD KINECT
Board

About Stephen K. Roddenberry

Stephen K. Roddenberry is Lead Independent Director of World Kinect Corporation and a long-tenured director, serving since 2006. He is a partner at the law firm Akerman LLP (since 1988) with expertise in corporate governance, securities, M&A and private equity, and is recognized for legal/regulatory and capital markets skills. Age 76; independent under NYSE standards; he presides over executive sessions of independent directors and reviews board agendas as Lead Director .

Past Roles

OrganizationRoleTenureCommittees/Impact
Akerman LLPPartner (Attorney)Since 1988Advises on corporate compliance/governance, securities, M&A, private equity
World Kinect CorporationDirectorSince 2006Lead Independent Director; Governance Committee Chair; Compensation Committee member

External Roles

OrganizationRoleTenureNotes
Not disclosed in proxyNo other public company directorships identified in WKC 2025/2024 proxies for Roddenberry

Board Governance

  • Lead Independent Director with authority to preside over executive sessions, liaise between independent directors and Chair/CEO, review agendas/schedules, call meetings, and retain advisors; board views role as a key independence safeguard .
  • Committee roles: Governance Committee Chair; Compensation Committee member; independent status confirmed by the Board for Governance and Compensation committees .
  • Board/committee activity: Board met four times in 2024; all directors attended at least 75% of aggregate Board and committee meetings; Roddenberry presides over executive sessions . Compensation Committee met seven times in 2024; Governance Committee met four times in 2024 .
  • Compensation Committee interlocks: none; no insider participation in 2024 .
  • Independence: All directors other than the CEO are independent under NYSE; committee compositions are entirely independent .

Fixed Compensation

  • Standard cash fee structure (2024–2025 term):
    • Board annual fee $100,000
    • Lead Independent Director additional $40,000
    • Committee member fees: Audit $15,000; Compensation/Technology & Operations/Sustainability & Corporate Responsibility $10,000 each; Nominating Subcommittee $5,000
    • Committee chair fees: Audit $35,000; Compensation/Technology & Operations $30,000; Governance/Sustainability $20,000; Nominating Subcommittee $15,000 .
  • 2024 cash earned by Stephen K. Roddenberry: $170,000; total director compensation $365,019 (stock awards $195,019) .
ItemAmount ($)
Fees Earned or Paid in Cash (2024)170,000
Total Compensation (2024)365,019

Performance Compensation

  • Equity awards structure (non-management directors, 2024): $175,000 RSUs for board service; additional $10,000 RSUs for Governance Committee membership; additional $10,000 RSUs for Governance Committee Chair; RSUs vest on earlier of day prior to next annual meeting or one year from grant; upon vesting, 100% of shares issued .
  • Roddenberry 2024 stock awards grant-date fair value: $195,019; RSUs granted for 2024–2025 term: 7,362 units .
  • Settlement schedule (as of April 10, 2025): 7,362 shares to be delivered June 2025; 16,679 shares delivered upon departure from the Board (vested/deferred units) .
Metric2024 GrantVesting / Settlement
RSUs granted (units)7,362 Vest earlier of next annual meeting or 1 year
Stock awards (grant-date FV, $)195,019 Settlement: 7,362 in June 2025; 16,679 upon Board departure
Performance metrics tied to director equityNone disclosed (time-based RSUs)

Other Directorships & Interlocks

CategoryDetail
Other public company boardsNot disclosed for Roddenberry in 2024–2025 proxies
Committee interlocksNone for Compensation Committee in 2024

Expertise & Qualifications

  • Corporate governance leadership (Lead Independent Director; Governance Chair) .
  • Legal and regulatory expertise, capital markets/M&A, private equity investment management .
  • Engagement: Led individual director interviews for 2023 board/committee self-evaluation; summarized results to Governance Committee and committees in early 2024 .

Equity Ownership

ItemValue
Beneficial ownership (shares)126,555; less than 1% of outstanding shares
RSUs/stock units held (Dec 31, 2024)24,041 units (RSUs); no deferred stock units disclosed for Roddenberry
Vested/settlement detail24,041 shares issuable from vested/will-vest units within 60 days; 7,362 delivered June 2025; 16,679 upon Board departure
Director stock ownership guidelinesMinimum of 5x annual fee ($500,000) within 5 years; all non-management directors compliant
Hedging/pledging policyHedging prohibited; pledging discouraged and requires prior approval; pledged shares don’t count toward executive ownership guidelines

Governance Assessment

  • Strengths

    • Independent leadership: Roddenberry serves as Lead Independent Director, enhancing agenda control, executive session oversight, and shareholder access—key checks and balances with combined Chair/CEO roles .
    • Committee influence: Governance Committee Chair with mandate over board composition, evaluations, principles, and director pay; Compensation Committee member with oversight of executive compensation and human capital .
    • Attendance and engagement: Board met four times in 2024 with at least 75% attendance; Roddenberry presides over executive sessions; led the qualitative self-evaluation process via one-on-one interviews in 2023—indicative of active board development .
    • Alignment: Meaningful equity via RSUs with structured vesting and deferred settlement until departure; directors meet ownership guidelines (5x annual fee), supporting skin-in-the-game .
  • Potential conflicts and monitoring points

    • Law firm affiliation: As a partner at Akerman LLP, potential related-party exposure would be a red flag if the firm provides services to WKC; no related-party transactions disclosed tied to Roddenberry in the proxy—continue monitoring 8-Ks and future proxies for any engagements .
    • Combined Chair/CEO: Mitigated by robust Lead Independent Director role and independent committee structure; maintain vigilance on executive session cadence and agenda-setting .
  • RED FLAGS

    • None disclosed regarding low attendance, say-on-pay issues, hedging/pledging by Roddenberry, or related-party transactions. Company-wide prohibitions on hedging and discouragement of pledging reduce alignment risk .